BACTERIAL VACCINES MARKET ANALYSIS

Market News

Recent Developments

New product launches

• On April 13, 2023, The University of Oxford and Serum Institute of India Pvt Ltd., a vaccine manufacturer, manufactured and scaled up R21/Matrix-M malaria vaccine, by leveraging Novavax’s adjuvant technology, that has been licensed for use in Ghana by the country’s Food and Drugs Authority.
• On December 2022, Biological E. Limited (BE), a pharmaceutical company, announced that its 14-valent paediatric pneumococcal conjugate vaccine, (Investigational Pneumococcal Polysaccharide Conjugate Vaccine PCV14) against S. pneumoniae infection received approval from the Drugs Controller General of India (DCGI) for manufacture and commercialization in India.
• In September 2022, Biological E. Limited (BE), a pharmaceutical company, announced that the Subject Expert Committee of CDSCO reviewed and approved the Phase 3 infants clinical trial data and recommended for manufacture of its 14-valent paediatric vaccine (investigational pneumococcal polysaccharide conjugate vaccine PCV14) against S. pneumoniae infection in single-dose and multi-dose presentations. The PCV14 can be administered to infants at 6, 10 and 14 weeks of age.
• In December 2020, Serum Institute of India, the largest vaccine manufacturer, launched India’s first indigenously developed pneumococcal vaccine – PNEUMOSIL which aimed at improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low-and middle-income countries such as Africa.

 Acquisition and partnerships

• On October 6, 2023, Amgen Inc., a pharmaceutical company, announced that it has completed its acquisition of Horizon Therapeutics plc., a pharmaceutical company, to serve even more patients around the world suffering from serious illnesses
• On October 5, 2023, Emergex Vaccines Holding Limited, a clinical-stage biotechnology company has announced a collaboration agreement with Vaccine Industrial Company (VIC), a Saudi Arabia based pharmaceutical company for advancing Emergex’s novel T cell-priming immune set-point candidates against designated infectious diseases. Under the term of collaboration, Emergex Vaccines Holding Limited is subject to government support of Phase II/III clinical trials of Emergex’s T cell-priming candidates for dengue, coronavirus, influenza, yellow fever, including add-on products related to these indications
• On February 15, 2023, Bavarian Nordic A/S, a pharmaceutical company, announced that it entered into an agreement with Emergent BioSolutions Inc., a pharmaceutical company to acquire two marketed travel vaccines, Vivotif for the prevention of typhoid fever and Vaxchora against cholera as well as a Phase 3 vaccine candidate for the prevention of Chikungunya virus
• In August 2022, GSK plc., a pharmaceutical company announced acquisition of Affinivax, Inc., a clinical-stage biopharmaceutical company. Affinivax has pioneered the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. It includes a next-generation 24-valent pneumococcal vaccine candidate (AFX3772), currently in phase II development, which is based on the highly innovative Multiple Antigen Presenting System (MAPSTM) platform technology. A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development.
• In April 2022, Pfizer Inc., a pharmaceutical company, announced acquisition of ReViral Ltd., a privately held, clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV)